Furthermore, BRAF inhibitors, by paradoxically activating the molecular pathway of MAP kinases, favored the development of secondary tumors, especially cutaneous squamous cell carcinomas, and the main cause of monotherapy failure was represented by acquisition of resistance mechanisms, mainly due to a reactivation of the MAP kinase pathway [17,18,19]. Here, BRAF is linked to cutaneous squamous cell carcinoma.